Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0038389992
Fri, 16.02.2024
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
February 16, 2024
Annual report of BB Biotech AG as at December 31, 2023
BB Biotech AG publishes its 2023 annual report
BB Biotech AG published its annual report for fiscal year 2023 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the bi [ … ]
Fri, 19.01.2024
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
January 19, 2024
BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors
In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information:
Results for the financial year 2023
Based on its preliminary unaudited [ … ]
Fri, 20.10.2023
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
October 20, 2023
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2023, which covers the results of its business activities for the first nine months of 2023.
Based on the consolidated accounts of BB Biotech AG, net loss [ … ]
Fri, 21.07.2023
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
July 21, 2023
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2023, which covers the results of its business activities for the first six months of 2023.
Based on the consolidated accounts of BB Biotech AG, net loss for the [ … ]
Fri, 21.07.2023
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
July 21, 2023
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2023, which covers the results of its business activities for the first six months of 2023.
Based on the consolidated accounts of BB Biotech AG, net loss for the [ … ]
Fri, 21.04.2023
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
April 21, 2023
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2023, which covers the results of its business activities for the first three months of 2023.
Based on the consolidated accounts of BB Biotech AG, net loss for [ … ]
Fri, 21.04.2023
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
April 21, 2023
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2023, which covers the results of its business activities for the first three months of 2023.
Based on the consolidated accounts of BB Biotech AG, net loss for [ … ]
Fri, 17.02.2023
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
February 17, 2023
Annual report of BB Biotech AG as at December 31, 2022
BB Biotech AG publishes its 2022 annual report
BB Biotech AG published its annual report for fiscal year 2022 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the bi [ … ]
Fri, 17.02.2023
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
February 17, 2023
Annual report of BB Biotech AG as at December 31, 2022
BB Biotech AG publishes its 2022 annual report
BB Biotech AG published its annual report for fiscal year 2022 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the bi [ … ]
Fri, 20.01.2023
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
January 20, 2023
BB Biotech AG closes the 2022 fiscal year with a loss
In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for its financial year 2022.
Based on its preliminary unaudited consolidated figures, BB [ … ]